Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

August 6, 2026

NASDAQ US Health Care Biotechnology earnings 84 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, everyone, and thank you for being with us on today's call. Today's webcast slides are available in the Investors & Media portion of our site, cytokinetics.com, together with the press release we issued today. Robert Blum, our President and Chief Executive Officer, will kick things off with a look at the quarter and what's happened recently. Andrew Callos, EVP and Chief Commercial Officer, will talk about how the commercial launch of MYQORZO is going in the U.S. and Europe. Fady Malik, EVP of R&D, will share updates on aficamten. Steve Heitner, SVP and Chief Medical Officer, will give updates on the clinical development programs we currently have underway. Sung Lee, EVP and Chief Financial Officer, will walk through the quarter's financials. Then, to wrap up, Robert will offer closing remarks and go over the key milestones for the year ahead. On this slide, you can see that forward-looking statements will be part of today's discussion, and those carry risks and uncertainties. For a discussion of those factors, please see our SEC filings. With that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate everyone being with us on today's call. For Cytokinetics, the second quarter represented yet another stretch of strong execution, defined by robust commercial traction for MYQORZO across the United States, our inaugural launch in Europe taking place in Germany, headway toward securing further market access around the world, possible regulatory catalysts in international markets, and ongoing progress within our later-stage specialty cardiology pipeline. Only 5 months after MYQORZO's commercial debut, we're seeing velocity pick up in a way that surpasses what we had anticipated. Andrew will walk through this, but the rise in prescriptions and dispensed volume for MYQORZO speaks to growing awareness, deeper physician involvement, widening patient access, and uptake spanning several segments of the targeted prescriber base — all of which bolster our confidence in MYQORZO along with its clinical, therapeutic, and commercial potential. We likewise carried out our global commercialization strategy effectively during the quarter, bringing MYQORZO to Germany as the first of a sequence of European launches we anticipate across the next 6 to 12 months. For Cytokinetics and for European patients alike, this marks a significant milestone, and it forms the groundwork for building wider access throughout Europe and further afield in the years ahead. Along those lines, more recently the MHRA awarded MYQORZO Marketing Authorization throughout the United Kingdom for treating symptomatic oHCM in adult patients. Simultaneously, NICE released guidance endorsing MYQORZO for use in England and Wales. It's gratifying that having the regulatory approval and the reimbursement recommendation arrive together will allow MYQORZO to get to patients faster. Later this year, we anticipate drug supply and a full U.K. launch. During the second quarter, we underscored aficamten's potential to treat the full spectrum of HCM when we reported top line results from ACACIA-HCM in nonobstructive HCM patients, which showed the Phase III trial achieved both of its dual primary end points, with statistically significant improvements from baseline to week 36 in KCCQ Clinical Summary Score and Peak VO2 versus placebo. For an nHCM patient population that has no approved therapies today, these findings constitute a major scientific accomplishment, and they mark a meaningful move toward extending aficamten's potential reach past oHCM — subject, naturally, to regulatory review and any subsequent approval. After we announced the ACACIA-HCM top line results, we sat down with the FDA to talk over our next steps. Together we went through the clinical trial results and raised questions that the FDA answered. Those conversations and the feedback from the FDA now shape our plan to file a supplemental NDA for aficamten in nHCM during the fourth quarter of this year. We intend as well to meet with EU regulators for comparable discussions supporting potential future regulatory submissions in Europe. Meanwhile, we're eager to share the complete ACACIA-HCM results in a hotline session at this month's European Society of Cardiology Congress. In addition to the strides we've made toward getting MYQORZO into the hands of more oHCM patients across the United States and abroad, we're putting priority on possible regulatory clearances for aficamten among nHCM patients, which might result in MYQORZO becoming the sole approved treatment for people spanning the broader HCM spectrum. What's more, during the second quarter, as you're going to hear, we kept pushing our later-stage specialty cardiology pipeline forward, with additional momentum shown in key clinical trials for novel drug candidates born out of our trailblazing leadership in innovative muscle biology and pharmacology; and we strengthened our balance sheet through a successful financing that backs our plans and objectives. When you put it all together, the headway we achieved in the second quarter highlights that Cytokinetics is performing strongly as a global commercial-stage, integrated biopharmaceutical company. We're generating commercial growth and velocity, broadening global scale and access, moving toward expanded product labeling and advancing the pipeline. All of it done with focus and discipline around capital access and allocation. I'm eager to tell you more about that shortly alongside my colleagues. So with that, I'll hand the call over to Andrew.

Andrew Callos

executive
#3

Thanks, Robert. During Q2, the rollout of MYQORZO kept showing robust expansion. Even though it's still early days, the consistent momentum we're witnessing in physician familiarity, prescribing behavior, patient interest, and payer access gives us confidence; we think these initial signals are starting to prove that MYQORZO's distinct profile is connecting effectively with health care providers, payers, and above all, patients. Since kicking off our commercial launch at the close of January, MYQORZO has posted quarter-over-quarter acceleration in new-to-brand prescriptions in the CMI category, rising 24% in Q1 and 15% in Q2, versus the single-digit growth rate seen when just one CMI was on the market. MYQORZO's arrival is helping fuel broader and deeper new patient starts, along with stronger involvement and recognition among a wide array of physicians and prescribers in the category. Indeed, in our latest market research survey, fielded in Q2, unaided awareness among HCPs climbed to 68%, up from 52% in Q1; we're likewise observing promising patient engagement. Our patient marketing campaign has fueled early and heightened awareness, producing over 30% awareness among oHCM patients in the United States; on top of that, we've delivered more than 390 million impressions and 2.1 million social media clicks via our focused and targeted digital media campaigns spanning a wide range of channels and platforms. We're also glad to observe sustained perception of clinical differentiation in MYQORZO's favor among HCPs. In our latest physician survey, carried out in May, HCPs keep favoring MYQORZO's clinical profile. The treating physicians we polled also regard MYQORZO positively on multiple attributes, such as convenience of dosing flexibility, safety and tolerability, and the flexibility tied to differentiated REMS requirements; at this point in our commercial launch, our focus stays on deepening prescribing among high-volume CMI prescribers. Historically, such physicians have accounted for roughly 80% of CMI prescriptions. Although our call universe covers over 10,000 health care providers, we are prioritizing engagement with high-volume prescribers. And by the close of Q2, our sales team had connected with over 90% of these HCPs; we intend to keep that same priority emphasis on high-volume prescribers until we reach greater than 50% new-to-brand prescription share, which we think could arrive by the end of this year, if not earlier. Meanwhile, we're encouraged by how much adoption is already expanding beyond the traditionally high-volume CMI writers; in fact, by the close of Q2, over 50% of MYQORZO prescribers were either low-volume CMI prescribers or first-time CMI writers. Our field force connected with more than half of these physicians in Q2. We view prescribing from this group as a key signal that MYQORZO is building momentum across a broader segment of the oHCM treating community, something we expected given MYQORZO's differentiated profile, and it's validating to witness that in actual prescribing. Also crucial is that our teams working in the field are presenting the MAPLE-HCM data to physicians who treat oHCM; this key information from our second Phase III study of aficamten reinforces what SEQUOIA-HCM showed and goes further in demonstrating that MYQORZO outperforms the beta-blocker metoprolol — a meaningful differentiating factor that clinicians respond to, strengthening confidence in MYQORZO's safety profile, effectiveness and clinical value for oHCM patients. As promised when we launched, we keep assessing our performance through 3 core metrics: prescribing breadth, captured by counting the HCPs who have issued prescriptions; prescribing depth, captured by counting how many patients each HCP has prescribed MYQORZO to; and patient volume, which captures the overall count of distinct patients given a MYQORZO prescription. On all 3 of these metrics, the quarter's progress and pace of growth have been encouraging to us. When the quarter closed, over 700 distinct health care providers across the U.S. had written a MYQORZO prescription, among them roughly 300 physicians belonging to the high-volume CMI writer group; on average, each HCP prescribed MYQORZO to about 3 of their patients, and that number is higher still within the subset of high-volume CMI writers, who by now have prescribed MYQORZO to roughly 5 patients apiece on average. While syndicated data has limitations that make an exact calculation of new-to-brand Q2 exit share within the CMI category difficult, our own internal review indicates MYQORZO's exit share climbed past 40% during the second quarter. We're likewise still seeing positive leading indicators of demand ahead, among them over 25 health care — 2,500 health care providers who have finished REMS certification as of launch. Now to patient demand. During the first quarter, we disclosed roughly 680 MYQORZO prescriptions, with 400 of those dispensed to patients before Q1 ended. When the second quarter closed, MYQORZO had been dispensed to 1,500 patients — close to a tripling in the count of new patients receiving MYQORZO during the quarter. Most prescriptions keep getting dispensed in about 3 weeks, after all patient documentation and benefits investigation wrap up. Moving forward, our plan is to report patient dispense alongside prescriptions so we align better with product revenue. During Q2, more than 80% of dispensed prescriptions were paid for, with the rest tied to free trial, bridge or other patient assistance programs. These are similarly encouraging signs of commercial launch growth and velocity. On the access front, we hold to our goal of broad coverage throughout key payer channels. We finished the quarter with close to 90% parity coverage for Medicare lives; we're also still expanding our commercial wide coverage, reaching beyond 50% commercial coverage by the close of the quarter, and we remain on schedule to reach parity access before the end of 2026. Beyond the United States, we successfully brought MYQORZO to Germany in June to help broaden access across Europe, and we've additionally filed 10 HTA dossiers throughout Europe, with reimbursement approval taking effect August 1 in the Netherlands. Additionally, in England and Wales, NICE has issued guidance backing MYQORZO’s usage as we keep advancing efforts to expand the route toward more patient access, in key markets, with further markets expected to become available later this year during the first half of 2027; the results we’ve observed in our launch markets have us highly encouraged. The pace of uptake we’re witnessing speaks to MYQORZO’s differentiated profile, as well as the commitment and execution of our colleagues throughout the U.S. and Europe, who are delivering excellence with integrity and focus alike. So with that, I’ll hand the call over to Fady.

Fady Malik

executive
#4

Appreciate that, Andrew. For our HCM portfolio, the second quarter stood out as a significant stretch, and the headline item was our disclosure of favorable top line data from ACACIA-HCM, the pivotal Phase III study we ran in symptomatic nHCM patients. Through the top line press release we issued in May, we reported that ACACIA-HCM hit both of its dual primary end points, showing statistically significant gains versus placebo from baseline out to week 36 on both the KCCQ Clinical Summary Score and Peak VO2. Beyond that, we saw statistically significant gains relative to placebo on key secondary endpoints, and we didn't find any new safety signals. These findings strike us as especially meaningful, since they show what aficamten might do in nHCM — a group that makes up as much as 1/2 or more of the total HCM population and that currently has no approved therapies. For many years, patients with nHCM have had few treatment choices, even though the disease carries a substantial burden. In our view, the ACACIA-HCM results mark a meaningful move toward possibly rewriting that treatment paradigm. Later this month, we're eager to share the primary ACACIA-HCM results in a hotline session at the European Society of Cardiology Congress. That presentation of the primary results will give a fuller, more detailed picture of both primary endpoints, the secondary endpoints and, naturally, safety. There's also a late-breaker session where we'll share additional analyses looking at how aficamten influences cardiac structure and function, and that data ought to make the treatment effect of aficamten clearer in this patient population. While at ESC, we're planning to hold an event as well — available both in person and virtually — giving investors and analysts the chance to pick up perspectives and insights regarding the results from top HCM KOLs. As Robert mentioned, after the top line results became public, we met with FDA to review the ACACIA-HCM findings along with what comes next for aficamten, and that discussion informed our strategy to submit a supplemental NDA, which we expect in Q4 of this year. While getting ready for that submission, we also anticipate talking with European regulatory authorities along similar lines about a possible filing with the European Medicines Agency. Plenty of work remains, yet the favorable top line results and our regulatory conversations so far bolster our ongoing confidence in the opportunities for aficamten in nHCM; in oHCM, we keep supporting review activities and engaging constructively with FDA on the sNDA for MAPLE-HCM that's presently under review, with a PDUFA date of November 14, 2026. Our belief remains that the MAPLE-HCM results could meaningfully shape treatment guidelines and clinical practice by supplying evidence that backs using aficamten as an earlier option for suitable patients. At the same time, because the effectiveness and safety data for aficamten from MAPLE-HCM match what appears in our label, members of our field medical organization have been talking through those findings with doctors who might prescribe it. Beyond that, our field medical group continued to support the MYQORZO rollout. More than 800 scientific exchanges took place with health care professionals in the U.S., spanning many topics, including questions related to the USPI as well as the public disclosure we made about results from ACACIA-HCM. Our medical science liaisons also helped with introductory meetings for HCPs, lending support to our cardiovascular account specialists, known as CAS. During the quarter, our medical team members were thrilled to help kick off our very first investigator-initiated research study involving aficamten. That trial is looking at whether doctors can safely and effectively switch patients with oHCM straight from mavacamten over to aficamten, and whether it works. Taken as a whole, the progress we made during this quarter gives us more confidence about everything aficamten might be able to do across the entire HCM spectrum. And now that MYQORZO is on the market for patients — for adults who have symptomatic oHCM, I should say — and given the good ACACIA-HCM data supporting a potential move into nHCM, we continue to see a substantial opportunity to get this drug to a larger group of patients, in the U.S. as well as around the world. Alright, I'm happy to hand the call over to Steve Heitner. But first, I'd like to make it official: Steve is now our Chief Medical Officer. He joined Cytokinetics back in March 2020, and he'll continue to head up clinical research — overseeing how our trials are designed, run, and carried out — while also assisting in growing our pipeline and advancing our clinical research capabilities as we move into a new period of R&D powered by artificial intelligence. Given his background caring for HCM patients and his extensive knowledge of this condition, Steve has been a standout leader in the effort to deliver aficamten to patients. His contributions in insight and direction were enormous in securing approvals for MYQORZO across the United States, European Union, and China. In addition, he took on significant parts in shaping the novel trial designs and the high standard of execution for ACACIA-HCM involving aficamten, AMBER-HFpEF involving ulacamten, and COMET-HF involving omecamtiv mecarbil. What is happening now is a handing over of responsibility from Stuart Kupfer, our Chief Medical Officer at Cytokinetics starting in 2020, whose seasoned leadership and skilled supervision of clinical research, clinical pharmacology, and drug safety added tremendously to a great number of our achievements during recent years. We're glad Stuart is staying on at Cytokinetics in the role of Senior Vice President of Clinical Development, where he'll help advance our clinical programs and external innovation, with particular emphasis on pharmacovigilance. Steve, over to you.

Steve Heitner

executive
#5

Thanks, Fady. To begin with our existing aficamten initiatives, we're still pushing forward with research that will help make the drug available to more people globally. In Q3, we anticipate wrapping up how the Japan cohort of ACACIA-HCM is carried out, and our collaborator Bayer should finish running CAMELLIA-HCM, which assesses how obstructive HCM patients in Japan respond to treatment. We've also moved CEDAR-HCM forward — that's a trial looking at aficamten in pediatric obstructive HCM patients. As a matter of fact, enrollment for the adolescent cohort wrapped up this quarter sooner than we'd anticipated. Beyond the headway on aficamten, we're also continuing to move the rest of our cardiovascular pipeline ahead in Q2. Turning to omecamtiv mecarbil, COMET-HF — our confirmatory Phase III clinical trial involving heart failure patients whose ejection fraction is severely reduced — is still being conducted; we've enrolled a bit more than 1/3 of patients spanning North America, Europe, and China. Thanks to the extra sites brought on board in China during the past quarter, over 90% of the sites we planned are now up and running. It's encouraging to see that the baseline characteristics of these heart failure patients, along with how severe their condition is, are lining up quite closely with the subgroup of heart failure patients from GALACTIC heart failure with severely reduced ejection fraction — the ones in whom the treatment effect seemed most concentrated and who shaped how this trial was designed. We anticipate enrollment will keep going through 2026; as for ulacamten, we're still enrolling Cohort 1 of AMBER-HFpEF, our Phase II study involving patients who have heart failure with preserved ejection fraction, working toward finishing enrollment in the latter half of this year, as expected. Our attention stays on keeping the trial running and producing data that can help clarify what role cardiac myosin inhibition might play in heart failure with preserved ejection fraction. All in all, we're happy with how our later-stage specialty cardiology development portfolio keeps progressing, and we're eager for key milestones in the quarters ahead. With that, I'll pass things to Sung.

Sung Lee

executive
#6

Thanks, Steve. I'll begin with the top line. Our total revenues for Q2 landed at $28.6 million, compared with $66.8 million in the equivalent quarter of 2025. Net product revenues for MYQORZO reached $25.3 million, which will serve as the core engine of our revenue from here on. Breaking that down, U.S. net product revenues accounted for $23 million, fueled by strong demand, and over 80% of patients are filling paid prescriptions. In Europe, net product revenues contributed $2.3 million, which reflects the initial inventory that distributors bought in Germany. Rounding out total revenues for the second quarter, collaboration revenue added $3.3 million, up against $2.4 million in the comparable period of 2025. During Q2 of 2026, we didn't bring in any licensing or milestone revenue. That compares with $64.4 million in Q2 of 2025, when we saw milestones come through from our collaboration with Bayer for aficamten in Japan. Moving on to operating expenses: R&D came in at $97.8 million for the second quarter, versus $110.1 million during the same quarter in 2025. The drop largely reflects the heavier clinical trial work, supply chain expenses, and medical affairs efforts we had in 2025, partly offset by increased personnel-related costs this year. SG&A for Q2 totaled $104.4 million, up against $65.7 million for the comparable period in 2025. That rise came mainly from expenses tied to the commercial rollout of MYQORZO, our U.S. sales team, and greater personnel-related costs outside of sales, which includes stock-based compensation. For the second quarter of 2026, cost of goods sold reached $2.7 million, almost all of it stemming from a nonroutine charge tied to optimizing drug supply. Collaboration cost of revenues in the second quarter of 2026 totaled $2.9 million, versus $2.4 million during the same period in 2025, largely a result of reimbursing partner costs. Our net loss in the second quarter of 2026 came to $198.8 million, or $1.50 per share, compared with a net loss of $134.4 million, or $1.12 per share, in the same period in 2025. Let's now shift to the balance sheet. When the second quarter came to a close, our cash and investments stood at roughly $1.7 billion, up from $1.1 billion at the close of 2026's first quarter. The main factor behind that second-quarter rise in cash and investments was the public offering we completed in May, which brought in net proceeds of about $760 million. Let's move on now to financial guidance. For full year 2026, we're revising our GAAP combined R&D and SG&A expense to a range of $860 million to $890 million, which is up from the earlier range of $830 million to $870 million. We're changing our estimate for stock-based compensation that sits inside the GAAP figure combining R&D and SG&A. That number now moves to somewhere between $130 million and $140 million, whereas before we had said $120 million to $130 million. If you take stock-based compensation out of that revised GAAP combined R&D and SG&A figure, you land at a range spanning $720 million to $760 million. What's driving us to lift guidance is mainly the money we're putting into commercial readiness, which the positive ACACIA-HCM data set off, allowing us to support a potential 2027 launch of MYQORZO in nHCM. With that said, I'll hand it back to Robert.

Robert Blum

executive
#7

Thanks, Sung. Looking back at the opening six months of 2026, the headway we've achieved, in my view, shows how solidly we're executing and how well positioned we are strategically as a global growth company that's maturing. We're not even 6 months past our commercial launch, and the demand we're seeing for MYQORZO is encouraging — physician adoption is climbing, patient access keeps widening, prescriptions are broadening, use among doctors is deepening, and patient volume is up, all of which tells us our launch is building momentum. We also pulled off a successful launch in our first European market, and although our commercial journey is still young, the path we're seeing strengthens our conviction that MYQORZO could become the CMI of choice in oHCM. When it comes to aficamten, our near-term priorities are plain. In oHCM, first, we're carrying out successful global launches of MYQORZO and seeking further approvals throughout Europe. In nHCM, we're presenting the primary results from ACACIA-HCM at ESC and getting ready to submit an sNDA to FDA later this year, along with planning for commercialization in nHCM. Outside Europe, regulatory reviews for aficamten are still underway in a number of geographies, among them Canada, Hong Kong and Taiwan; at the same time, we keep assessing ways to broaden global access via potential partners in other regions beyond North America, Europe and Asia, where we think MYQORZO might address meaningful unmet need. Building our specialty cardiology franchise also depends on the promise of both omecamtiv mecarbil and ulacamten, and we're pleased that both are moving along well in their respective later-stage trials. Looking forward, I'd say our strategic positioning has never been stronger; we're moving into this next phase of growth with a strong balance sheet, which gives us financial flexibility to support MYQORZO's global commercialization and to keep investing across our pipeline, chasing opportunities that can boost longer-term shareholder value. Along with our expanding commercial presence, our growing clinical evidence base, and our advancing pipeline, we believe we're well positioned to create meaningful value for patients and shareholders in the years ahead. Now let me recap our 2026 milestones. For aficamten, we expect to submit a supplemental NDA in nHCM in Q4 later this year. And we potentially will receive FDA approval of the sNDA for MAPLE-HCM, also in Q4 later this year. We expect to prepare to launch aficamten in the U.K. later in Q4, continued conduct of the adolescent cohort of CEDAR-HCM throughout the year and potentially receive approval from Health Canada in the second half of 2026; for omecamtiv mecarbil, we expect to continue patient enrollment and the conduct of COMET-HF through this year. For ulacamten, we expect to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the second half of this year; and for CK-089, we expect to continue the second Phase I study — and finally, for preclinical development and ongoing research, we expect to continue those activities directed to additional muscle biology-focused programs. And operator, with that, we can now open up the call to questions, please.

Salim Syed

analyst
#8

Great numbers — congrats. Robert, Andrew, perhaps only a single item from our side about dispensed compared with prescribed. We're clearly getting a large volume of e-mails simply concerning the explanation here. Might you — so that we can have the apples-to-apples on the Rx; so I believe you mentioned it was 400 dispensed against the 680 in the 1Q and then 1,500 dispensed during this quarter. What would the Rx be for this quarter, if you could give us that? And would the 59% ratio hold steady across the 2 quarters if you'd rather not get too granular?

Robert Blum

executive
#9

Yes. I'll pass that along to Andrew to handle; but clearly, it's the dispensing that generates the revenue. That's why we felt it was key to get in line with that figure. Andrew, can you speak to the particular prescriptions and dispensing activity during the second quarter?

Andrew Callos

executive
#10

Absolutely, and thanks for raising that, Salim. Glad to walk through it. You've got it right — from 680 to 400 during Q1, then roughly 2,000 to 1,500 across Q2, cumulatively since launch. That gap represents patients still pending. What we're talking about are people moving through the steps. When a script comes in, that essentially reflects the demand underneath, and that hasn't shifted. In fact, as the new-to-brand market share figures we shared indicate, underlying demand is growing. Still, there's a workflow involved — REMS enrollment must take place, a prescription must be written, signatures are needed from both the physician and the patient, then benefit investigation, and frequently prior auths. All of that means a process spanning a number of weeks. Each week we're seeing roughly 100-plus prescriptions come through. So most of that gap comes down to patients pending while their prescription works its way toward being filled and dispensed. A modest mid-single-digit share of prescriptions do end up canceled, yet the overwhelming majority remain in process and will ultimately result in a dispense. I hope that addresses your question.

Salim Syed

analyst
#11

Okay; so about 2,000,

Andrew Callos

executive
#12

Yes, you got it.

Roanna Ruiz

analyst
#13

I'm interested in the various metrics you're monitoring for the MYQORZO U.S. launch, at a high level. Is anything picking up speed more than other things as we move through the quarter? And might you speak to what's visible regarding switches compared with new patient starts? Is that ratio staying consistent with the prior quarter? Or is there some movement there?

Robert Blum

executive
#14

Okay. Perhaps I'll hand that over to Andrew as well?

Andrew Callos

executive
#15

Absolutely, I appreciate you asking that. So a few shifts are showing up. First, a larger share of scripts are being paid for, and that's a positive sign. The amount of time it takes for that script to get paid is roughly unchanged. We're noticing a pickup when it comes to low-volume prescribers who are writing for first-time members on CMI, from a switching standpoint, and each of those things points clearly to wider prescribing. On switching, what we shared was quite low single digits; what we're truly observing is likely somewhere between 5% and 7% of all our dispenses coming by way of switching. Switching has ticked up a bit, though not in any dramatic fashion, and it isn't a significant factor.

Carter Gould

analyst
#16

I'm running some quick calculations here, but it looks like total classes, whether you count them monthly or weekly, have only risen slightly, and what you seem to be getting right now is mostly taking share rather than expanding the market. Would that be a reasonable way to put it? And on a different note, a clarifying question: did stocking play any role in that $23 million number?

Robert Blum

executive
#17

Andrew, once more, I'll hand it over to you.

Andrew Callos

executive
#18

Yes, so growth really is picking up. I walked you through the overall rise in new-to-brand prescriptions. Last year, at least based on syndicated data, we were looking at roughly 2,000 new prescriptions each quarter. In the first quarter, that figure was likely about 2,500; by the second quarter, it's beginning to get close to 3,000; so what you're seeing is more new patients coming into the market. And overall, compliance and persistency haven't really shifted. So patients dispensed are going up; and I'll pass the question to Sung on stocking as it relates to revenue.

Sung Lee

executive
#19

Absolutely. Thanks, Carter. So when demand rises, our distributors are going to hold more inventory, but that inventory is in line with the demand. So this quarter was driven by demand.

Ash Verma

analyst
#20

Yeah, so I've got a question that's somewhat similar, but it's about prescriptions along with dispenses. So I recall that whenever you gave the update for the first quarter, you brought up the April prescription figure. And if I were to take that number, 420, and then apply 60% to it, that gives me 250 dispensed for April, whereas when you did it across the whole quarter, it comes to something like 1,500. So 250 happened in 1 month. And then you've got 1500 for the entire quarter, so as you think about it on a month-over-month basis, are you observing a greater acceleration in growth right now? And is there anything you're able to share regarding how July has been shaping up?

Robert Blum

executive
#21

Well, we're going to hold back from discussing July, but Andrew, could you address the second quarter?

Andrew Callos

executive
#22

Yes. From those ratios, it's clear we're seeing dispense growth. Once managed care and access stabilize, my expectation is that dispenses will plateau — frequently that's the period for a patient who's pending. Certifications required mean the REMS definitely contributes, yet a pending patient tends to remain impending for a longer stretch owing to the benefits investigation plus a prior auth process. Shrinking that period is something we'd aim for eventually, though near term I don't expect it.

Tessa Romero

analyst
#23

So if we zoom out a bit, with ESC approaching in just a few weeks, what do you think physicians and investors will have a clearer grasp of once the conference has wrapped up? And then, second, to dig into this a little more, you mentioned getting to 50% new-to-brand share before the year ends, possibly earlier, for MYQORZO. Given that, where do things stand at the moment?

Robert Blum

executive
#24

Let's begin with your first question about ESC, and what could be fleshed out compared with what our top line press release has already put out there. First off, we've stated plainly that once we present the more complete data, we think investors will have a clearer sense of what we intended with terms such as consistent and robust. Now that we're able to discuss the size of change across every endpoint, secondary endpoints included, and explain why we see that as a highly consistent, robust efficacy narrative as measured through those different endpoints. Perhaps I'll turn to Fady and Steve, in case they'd like to add more on that, before we get to your second question, which has to do with a share of new scripts.

Steve Heitner

executive
#25

We therefore possess the headline results, which essentially follow the endpoints specified in the SAP; however, those will be placed into context both clinically and mechanistically. So the clinical picture is going to be discussed by Dr. Masri during his Friday talk; after that, on the Saturday, you will find the echo analysis being presented by Dr. Hegde, in which we'll address the mechanism through which patients are gaining these clinical benefits. And I believe that will prove quite illuminating for scientists and patients, ideally going forward.

Robert Blum

executive
#26

Therefore, my view is that once the full dataset is shown, we will be in a position to discuss far more thoroughly what the impacts are, how they appeared over time, and eventually across endpoints assessing both function and quality of life. As for your follow-up, let's go to Andrew. I believe he has partly covered it already by mentioning that more than 40% of new prescriptions in the second quarter came from that source, but Andrew, is there anything further you would like to add?

Andrew Callos

executive
#27

Right. That figure is what we're giving you for exit share once Q2 wrapped — in other words, during June our new-to-brand share came in above 40%. So July won't be part of our reporting. We'll cover the third quarter on that call.

Robert Blum

executive
#28

Tessa, quickly, if not faster — what we're seeing in these patterns is that a larger share of new prescriptions are going to MYQORZO than we might have anticipated. And regarding going beyond what was anticipated, we're launching quite forcefully when it comes to new prescriptions, while recognizing a portion of that may only be temporary. My view is that we'll remain cautious about the timeline for when we could anticipate majority share. Yet without a doubt, things are advancing quite rapidly toward that.

Akash Tewari

analyst
#29

Manoj here, filling in for Akash. We've just got a single question from our side. Have any prescribers who moved away from Camzyos shared anything with you, particularly regarding how well it works at reduced doses? And roughly what share of your newly started patients come from outside the center of excellence's care?

Robert Blum

executive
#30

If I've got your question right, are we picking up anything regarding mavacamten when it comes to lower usage and prescribing...

Analyst

analyst
#31

Yeah, regarding patients moving over from mavacamten — how does that compare with what you see in terms of efficacy when aficamten is given at the smaller doses?

Robert Blum

executive
#32

Right. So commenting on Camzyos and reduced dosing really isn't something for us to do. That said, Andrew, do you have any thoughts on aficamten and MYQORZO — specifically around how the dosing gets titrated — and could you then take on the second question, the one about prescribing beyond velocity accounts?

Andrew Callos

executive
#33

Absolutely. Regarding how it's administered, we have some latitude in the timing. With every echo, a physician is able to raise the dose, and that interval is showing up in actual practice, with certain patients receiving doses in as little as 2 weeks while others have their dose escalated over a period stretching to 2 months. What drives that really comes down to center logistics, the patients involved, and how physicians schedule. So that interval applies to each and every dose change. As for how widely and how deeply it's being prescribed, our breadth mix looks quite solid. Most of our prescriptions and prescribers fall into that high CMI category, roughly 40% of the total. The low volume group accounts for around 30%, and the CMI naive group — those who hadn't written a CMI before we came to market — makes up 30% of our prescribers. So across a wider set of prescribers, we're performing quite well. When we speak with those CMI-naive prescribers, what we hear anecdotally lines up with the differentiation shown on that slide. It essentially boils down to the REMS, the dosing window, the flexibility in dosing, and the absence of DDI monitoring within the overall REMS program. Those are the reasons we hear from them — mainly from that CMI naive group — regarding why they'd start a CMI at this point. I hope that addresses your question.

Robert Blum

executive
#34

When you consider what might be a positive sign for beating prescribing forecasts later on, it comes down to prescription volumes, refills generated by every one of those segments, plus growth in the category itself. Andrew, I believe, addressed both points during his prepared remarks. What's particularly encouraging is watching the high-volume writers produce the prescription counts they're producing, and on top of that, the fact that half of all prescriptions originate from people who had previously been new or low-volume prescribers — to me, that points toward category expansion, which is exactly what you ought to anticipate from us.

Paul Choi

analyst
#35

Sorry about the noise in the background. When you consider what you're doing to commercialize over the next year, you're going to introduce in symptomatic oHCM frontline oHCM and after that nHCM, and that means a great deal of data gets placed before physicians. And when you think about your messaging, perhaps make clear to us how you'll sort of approach all of these opportunities and put them in front of physicians while your sales force is out in the field during the next year.

Robert Blum

executive
#36

Yes; so perhaps I'll have both Fady and Steve begin, since clearly they sit at the leading edge of these studies, and as those get reported, presented and published, the medical colleagues already are discussing some of these things. And from that point Andrew and his commercial team take over. So Fady, would you like to begin and then Andrew after that?

Fady Malik

executive
#37

Yeah. So the starting point, really, is getting the data out there via the published literature. And Steve and the group working with him have been extremely prolific — not only with the main publications, but also with follow-up publications that build upon the original findings. Beyond that, the folks in our medical affairs group are in ongoing contact with the very top prescribers and physicians who treat these HCM patients, delivering the information to them and guiding them through it in a way that's concise yet thorough. And lastly, by running quite a few educational initiatives, whether as CME or as symposia sponsored by industry. So it's a fairly comprehensive effort, going from the primary publications all the way to getting the information out through many different channels. And in the end, our commercial teammates will take what makes it into a label and then be in a position to spread that information widely across their customer base as well. So great question. Andrew, would you like to respond?

Andrew Callos

executive
#38

Absolutely, and I could perhaps build on that from a commercial perspective. Having such a large volume of data within this timeframe represents quite a significant opportunity. Regarding Maple, we've conducted extensive research on this topic as well. From a physician's perspective, it expands their thinking about which individuals might be suitable candidates for a CMI, so we will definitely emphasize that point to doctors. This holds particularly true for those who prescribe infrequently and for CMI writers who are inexperienced—meaning they haven't prescribed it previously—since they clearly believe they have the right patient when comparing such a person against a beta blocker. Guidelines would undoubtedly drive that further if a change occurred in 2027; nHCM would then simply widen the range of patients a physician and a cardiology practice could manage using a single agent, MYQORZO, provided it gains approval for nHCM to address a wider variety of patients. Thus, our messaging has been rolled out in stages. Our communications are deployed in phases, and so on, and I believe we'll be prepared to capitalize fully on that added differentiation if those regulatory approvals materialize.

Robert Blum

executive
#39

Paul, regarding what you asked, our approach is to keep things straightforward; and one thing that makes me particularly happy is the strong cross-functional teamwork we have here at Cytokinetics. You raised the topic of publications and communications in this field. Another thing I'd point you toward is how many secondary manuscripts and other publications exist that extend from the primary manuscript. There is a wealth of information out there helping physicians understand the best way to think about aficamten, MYQORZO. And I genuinely believe that has led to awareness, meaningful education and pull-through in patient demand, which in turn lets our commercial colleagues perform so well. So credit goes to the medical colleagues who get it done on the publication side, and then the commercial people are able to keep things straightforward when they're out in the field detailing physicians.

Jim Condulis

analyst
#40

Congratulations on everything that's been accomplished. Turning to the nonobstructive side, I'm just wondering — now that you've begun the sNDA talks, do you anticipate any label or REMS variations if nonobstructive gets approved? Any details would be great.

Robert Blum

executive
#41

Sure. It's too early to address that. Clearly, we haven't submitted the sNDA yet, and we haven't talked with FDA after they've reviewed a submitted NDA — but my expectation is that, since this could be a separate trial, certain differences will need to capture nHCM as opposed to oHCM, though perhaps we ought not get ahead of any of that until we've actually engaged with FDA once the submission is in.

Jason Butler

analyst
#42

Nice work this quarter. Robert, could you take us through what you're expecting from ulacamten's cohort 1? Specifically, what do you think that group can teach us regarding the safety profile, plus PK/PD?

Robert Blum

executive
#43

Absolutely. I'll hand that question to Fady.

Fady Malik

executive
#44

Right, so like we've mentioned previously, AMBER-HFpEF is essentially a trial designed to determine dosing, and it's meant to help us grasp how ulacamten's distinctive mechanism could potentially manifest within the AMBER-HFpEF population. So we'll begin with PK. We'll examine a broad range of cardiographic parameters. Naturally, safety data will be included. And we'll additionally get a sense of whether it's feasible to enroll a group that's targeted toward the area where we believe a mechanism such as ulacamten's could have the greatest effect. So I believe throughout the duration of this study, that will assist in guiding ulacamten's ongoing development for this particular indication.

Cory Kasimov

analyst
#45

Josh here, filling in for Cory. At present, what share of the oHCM market has CMI managed to penetrate? And for this class, what peak penetration do you expect could be reached?

Robert Blum

executive
#46

In that case, perhaps I'll hand it over to you, Andrew, if you don't mind?

Andrew Callos

executive
#47

Therefore, we estimate somewhere between 110,000 and 120,000. That figure isn't merely speculation—it comes from analytics work we've completed from an Epi standpoint, and roughly that quantity represents the eligible patient population, assuming no rise in diagnosis. There are likely somewhere between 20,000 and 25,000 treated patients, which gives you penetration around the 20% range. Regarding peak penetration, I believe it will hinge over time on access, demonstrated safety of REMS programs change, and so forth, but my expectation is peak penetration somewhere in the 60% to 70% range.

Robert Blum

executive
#48

Right. So what Andrew mentioned implies there's still quite a distance ahead. We have yet to witness CMIs reach more than half of the people diagnosed and eligible, and there may be additional individuals who could receive a diagnosis now that new therapies exist for such patients. So this marks the start of what we hope becomes MYQORZO getting into an increasing share of those patients. But let's say we're nearer to 20% of everyone eligible at present, and that figure — with any luck the denominator expands.

Leonid Timashev

analyst
#49

About COMET — considering how quickly enrollment is going, how do you view the interim’s timing, and what are your expectations for it? And then, in the end, what would count as clinically meaningful in COMET?

Robert Blum

executive
#50

Fady, would you take that?

Fady Malik

executive
#51

Yeah. The rate at which patients have been signing up for COMET has felt quite good to us across the past several months, and I'd put it this way: we aren't giving any specific guidance about the timing we expect enrollment to wrap up, though it will definitely stretch into early 2027. Stopping the trial for efficacy at the interim analysis requires clearing a fairly high bar. So I wouldn't really say — my own expectations for a halt at that interim look are quite low, since only a very tiny slice of alpha gets spent at that point. From a clinical standpoint, we believe anything — the study was built, and this is something we always aim for, to design a study with a patient count you believe will show a minimally clinically beneficial effect, rather than overpowering it to demonstrate de minimis effects, so to speak. So the trial's powering kept that in mind, and I believe it ought to come out statistically significant somewhere around 0.86, 0.87, 0.88 in that ballpark for the hazard ratio on the primary endpoint. Naturally, though, I think once you examined that treatment effect in GALACTIC, we observed larger treatment effects there, and we're hoping that shows up in COMET too. I hope that answers what you asked, Leo.

Amine Chaherli

analyst
#52

Nice quarter, congrats. Amine here, filling in for Mayank. One question directed at Andrew regarding the NBRx share exit above 40%. What will drive that to 50 plus before year-end? Is it mainly those 300 high-volume docs prescribing more deeply? Or does the remaining Velocity group need to contribute as well? And on a related note, once the complete ACACIA data is presented at ESC, what impact do you expect that to have on oHCM prescribing in the near term?

Robert Blum

executive
#53

Andrew, would you like to address that?

Andrew Callos

executive
#54

When we talk about how we reach that goal, no single segment is going to carry us there. What it really comes down to is sustained penetration across every segment. For us, a velocity account was defined as 80% of the market, and who the Velocity prescribers are is genuinely changing relative to who they were at launch. So what we expect is that doctor by doctor — particularly at academic centers and centers of excellence, where we definitely intend to keep building share the way we have with most of them — we'll also bring on board the CMI-naive group, plus a group that really hasn't prescribed much in the way of a CMI. A lot of those were referring. And regarding nHCM, to address your second question, clearly it isn't approved, so we won't promote it or talk about it before approval. That said, it will be published in the public domain. Our expectation is there will likely be some sort of overhang effect, so to speak, when it comes to more prescribing. Once you have a third clinical trial — the obstructive HCM 2 trials with SEQUOIA and MAPLE, and a third with ACACIA — the ongoing safety data, with efficacy too, is quite reassuring to a physician. So I believe all of that together will make a difference in oHCM. So we expect to keep growing share as time goes on. And as we've consistently stated, our aspiration is to hold more than 50% of the share by year-end. We are definitely on track to accomplish that.

Maxwell Skor

analyst
#55

So when we look at what happened with Camzyos, what's the right way to think about persistence as the treated base grows? And given the differentiated dosing and titration regimen, might it look different for MYQORZO? And then, if I may, any views on seasonality, or on how we should frame quarterly cadence as we head into 2027?

Robert Blum

executive
#56

Andrew, do you want to take that?

Andrew Callos

executive
#57

Absolutely, so when we look at it from a retention standpoint, what we're anticipating is that things will stay level, or maybe even a bit stronger where Camzyos is concerned, simply because of how these drugs are characterized and a few of the initiatives that were introduced. Still, I'd say it's fair to expect something comparable, or perhaps modestly better, for MYQORZO. As for your other question, it had to do with — could you say that portion once more? I'm not certain I caught it.

Maxwell Skor

analyst
#58

Yeah. Do you have any perspective on seasonal patterns, or what sort of framework we ought to use for the quarterly rhythm as we move toward '27?

Andrew Callos

executive
#59

Well, what I'd say is — there's typically a slowdown just ahead of — actually right in the middle of a holiday week. Things level off over the summer months. Doctors take time off or go on vacation, and so do patients. Then we notice a pickup once more during the fourth quarter. So as far as seasonality goes, it tends to cluster around holidays, which matters only slightly, though the bigger effect is that leveling off across the summer, particularly during July and August.

Dominic Lorenzi

analyst
#60

Dominic here, filling in for Yas. Nice work on the quarter. One quick thing about the European launch — how do you see that playing out, particularly while you keep making headway with the U.S. launch and rollouts in other European nations? Do you expect it to serve as a catalyst for later launches?

Robert Blum

executive
#61

Sure, I can kick things off, then I'll turn it over to Andrew and maybe Sung for their thoughts. Making sure MYQORZO reaches patients across Europe is something we're deeply dedicated to. With our attention on select countries, plus partnership talks when it comes to the rest, we think we can get that done. That said, we're clear-eyed about what actually drives the revenue line, and obviously that's going to be mainly the U.S. business. Even so, we've had a strong beginning in Germany. We're quite happy with the early traction we gained there when it came to stocking, really just during the final few weeks of the quarter. And now we need to make sure we'll be generating demand and pull-through. Andrew, would you like to address what to expect in Europe versus the U.S.? And Sung, anything further you'd like to add once that's done?

Andrew Callos

executive
#62

Yeah, absolutely. So looking at it from a German perspective, things are still at an early stage. Our launch there only happened in June. There's a lag in the data, but what we've observed so far, beyond the stocking, meets or even exceeds what we expected for Germany. As for other big markets, reimbursements are beginning to come through. We've already discussed England and Wales. We've also mentioned the Netherlands; we likely have one significant market going live around the end of this year, and several more in the first half of next year. Building up Europe requires more time — on the revenue side, pricing falls within the 10% to 20% range; so I'd anticipate that Europe will contribute, though it won't be a growth driver. Eventually, it will probably account for around 15% of our total revenue, but perhaps Sung would like to add something to that.

Sung Lee

executive
#63

Yeah. Andrew did a good job of describing how things are moving along in Europe. Because we have to go through the HTA process country by country, the rollouts come at different times, and the U.K. is probably the next market we'll enter in Q4, with additional launches following into 2027, continuing right up until the close of 2027.

Robert Blum

executive
#64

We're not brushing aside how tough it is to launch in the US and several European nations all at once. Still, I think we're doing a strong job in each of those markets, and we're laying the groundwork for what shareholders care about, such as growth on the top line.

Srikripa Devarakonda

analyst
#65

Nice work on the quarter. With the launch trajectory you're currently observing and the November PDUFA date for MAPLE, how do you think a possible approval might alter that trajectory? Would you anticipate it having an instant impact? Or is it your view that educating physicians further about MAPLE could require some time? And then a brief follow-up regarding the physicians who hold REMS certification — it appears roughly 1,400 of them are REMS-certified. Could you remind me what share of those have written a prescription for the drug, and are you encountering any bottlenecks in the transition from certification to prescription?

Robert Blum

executive
#66

Andrew, would you like to take those on, please?

Andrew Callos

executive
#67

Alright, so starting with REMS and working backward from a certification standpoint: among patients who receive a prescription versus those certified under REMS, the proportion comes to roughly 30%. Week after week, enrollment in REMS keeps coming in. That definitely signals an intent — a focus on prescribing generally. In some cases, certification happens and then a different physician within the same institution writes the prescription. So it serves as a solid leading indicator of future prescribing. And once more, we have confidence that such growth will persist, driven by prescribing across a broad base. Regarding MAPLE, if MAPLE were — supposing MAPLE were added to the label, that clearly gives us more promotional capability. The 2 items I mentioned before that MAPLE genuinely accomplishes are, first, it creates a picture, particularly for low to nonprescribers, of which patients are appropriate for a CMI, and it expands or broadens how they think about who that appropriate patient is. Second, it clearly boosts preference share and market growth; so there's sort of a multiplier effect at play. Should guidelines be updated with respect to MAPLE, that would certainly — since a lot of physicians prefer to follow and comprehend guidelines — act as an additional accelerator, though clearly that would require additional time. So to address your question directly, my expectation is that we'd see some degree of impact, whether it becomes noticeable immediately at launch or whether it takes a while — I'd expect it will likely take a while more probably than a sudden large bolus of prescribing change.

Eric Joseph

analyst
#68

I'd like to circle back to what we were saying regarding HCPs — or rather, those HCPs who hold REMS certification — in light of the expansion you recorded over the last quarter. Could you describe how that figure stacks up against the count of REMS-certified prescribers, or prospective prescribers, for Camzyos? And once everything is up and running, what would that figure ultimately look like?

Andrew Callos

executive
#69

What you're getting at, I think, is how the number of certifications we hold under REMS measures up against the corresponding figure for Camzyos — is that right?

Eric Joseph

analyst
#70

Right, and then roughly how many providers do you think could end up REMS-certified across the U.S.?

Andrew Callos

executive
#71

Understood; regarding the Camzyos REMS certification figure, I'm not able to say anything. That number isn't something I have. Whether it gets reported, I don't need to know. Early in their launch, I'm aware BMS did report it, and at some stage they quit doing so. As for what we expect, we built our field force around 11,000 prescribers. Roughly 80% of HCM treaters fall within those 11,000 prescribers. That means most of them are clearly on beta blockers, calcium channel blockers. So we headed toward where we believed the market would move as CMI penetration grew over time; thus with oHCM, should nHCM win approval, we anticipate that the prescribing base, currently about 3,000 altogether, will rise to somewhere in the 7,000 to 10,000 range; therefore, down the road, my expectation is we'd hold more than 5,000 REMS certifications, yet we're pleased, extremely pleased with how fast it's going. That pace is exceeding the prescriber count, which is precisely where we want it to be.

Robert Blum

executive
#72

When it comes to beating what was expected, the figures we're looking at involve REMS-certified HCPs and how quickly that turns into new prescriptions prescribers, particularly beyond velocity accounts.

Yanan Zhu

analyst
#73

Thanks, and nice work on the quarter. I wanted to ask about your FDA dialogue concerning the nHCM indication filing. I'm just wondering, has the agency raised any specific questions or areas of emphasis? Then a brief one about dosing patterns — what final doses do patients end up on commercially? And is that the same or different from what you saw in clinical trials?

Robert Blum

executive
#74

I'll have Fady address that. But a word of caution: we don't typically provide a play-by-play on ongoing FDA interactions. Then perhaps Andrew and Steve could discuss the doses we're observing in patients, commercial versus clinical?

Fady Malik

executive
#75

Okay. I believe that when we shared the data, the obvious things anyone would ask while looking at a product for possible approval in that indication involve how clinically meaningful the endpoints and results are. The safety profile that came out. The way we could apply those findings and grasp how they interact with the patient group. Those, I'd say, are a few of the main threads we talked about, without going into too much detail. And I think we're in a strong position to handle whatever questions come up in those areas.

Robert Blum

executive
#76

One thing I can mention is that we felt good about the absence of any unexpected developments; and at this point, Andrew, would you like to address the dose levels that patients are already reaching in commercial use, and after that Steve can offer his thoughts on that within the setting of clinical research.

Andrew Callos

executive
#77

Right, absolutely. So what we're observing is a wide spectrum of dosing, reaching as high as 20 milligrams. Given how many new patients keep coming to us, I believe it's premature to say precisely how the mix will end up. Physicians and patients are making use of that window of 2 to 8 weeks for dosing. So that's definitely a thing we're tracking and working to figure out precisely how dosing will line up against clinical trials. Usually, from what I've observed, dosing tends to end up a bit lower as a percentage in clinical trials, but we will definitely share that figure down the road. Steve, is there anything you'd like to add?

Steve Heitner

executive
#78

I mean, there's not much to add beyond the plain fact that in the clinical trial, most patients wound up receiving the 15-milligram and 20-milligram doses — that holds true in MAPLE, in SEQUOIA, and in the data we released from the FOREST experience.

Robert Blum

executive
#79

This creates a chance to highlight something about MYQORZO that we consider significant: patients are able to increase their dose, and that supports convenience as well as flexibility, so doctors and those they treat can feel confident about advancing to the dosage that probably delivers the optimal trade-off between how well it works and how safe it is, with no need to settle.

Serge Belanger

analyst
#80

Perhaps the opening question is for Andrew. Your slides referenced < >. Do we have any signal right now regarding whether those prescribers with high volumes will keep utilizing the two products? Or will they ultimately choose only one? Then, second, for Robert: during your FDA meeting, was there any conversation regarding a possible priority review for the nHCM sNDA coming up?

Robert Blum

executive
#81

Andrew, I don't know whether you caught that entire question. Did you receive it?

Andrew Callos

executive
#82

Serge, I appreciate the question. I believe I grasped the core of it right at the start — it arrived quite fragmented. It's not my expectation that most prescribers will commit entirely to one option or the other. There are, without a doubt, some who champion a particular product and write prescriptions accordingly. Over time, the overwhelming majority will turn to both products. We anticipate that for most prescribers, MYQORZO will see heavier use than Camzyos, which is why we aim for a share above 50%, but I don't foresee us capturing 100% share among most prescribers, or anything close to that. Robert?

Robert Blum

executive
#83

On your point regarding the FDA and whether a priority review is reasonable — we're not going to say anything further about the particular back-and-forth we've had with the agency. That said, as has already been made public, setting aside whatever exchanges occur with the FDA, calling it unreasonable wouldn't be fair. Assuming a priority review could come through is a fair position to take. That isn't what we're assuming as the base case, though it would obviously be excellent if it came to pass. And we'll see whether we're able to bring that about.

Jason Zemansky

analyst
#84

Nice work on the quarter, and thanks for making room for us. Perhaps to follow up — this could be the final question. I believe you mentioned that roughly 5% to 7% of MYQORZO dispenses go to patients changing therapies. Which main reasons are behind those changes? And for those moving over from mavacamten, what kind of feedback are you receiving about keeping symptoms and gradient control in check?

Robert Blum

executive
#85

Right. Clearly, our grasp of this isn't organized enough for us to describe it with real precision; still, we do pick up anecdotes. Steve, maybe you'd like to weigh in on what could lead a physician to move a patient from Camzyos to MYQORZO?

Steve Heitner

executive
#86

Sure. Before I address that, let me note that MAPLE-HCM permitted prior mavacamten exposure, and in that context those subjects were expected to show a therapeutic response to aficamten. Then, regarding what Robert said, we think there are certain pharmacologic advantages that fit particular patients better, and the first of these involves how quickly the drug takes effect and how quickly it wears off; so for patients who might have specific indications requiring them to begin and cease the drug with fast onset and offset. Such patients would naturally be chosen for aficamten. People who are thinking about having children — as you may know, the Camzyos label carries a black box warning, as does MYQORZO. Conversely, it definitely has not been studied, yet based on our preclinical data it is not a black box warning. Drug-drug interactions are something you know about well. Patients who have done well on particular antidepressants or treatments for conditions such as gastroesophageal reflux disease might not want to change medications just to begin a new therapy for their hypertrophic cardiomyopathy. That would be one more reason to favor MYQORZO in clinical practice.

Robert Blum

executive
#87

Perhaps I can add just a little to what Steve mentioned. Driving switches is not — it is really not what our strategy is about. What we're seeing is that a number of physicians are raising questions regarding how to switch, and some investigators decided to run a study that would shed light on that practice, should there be interest in it. But as Andrew discussed regarding prescribing, new prescriptions, and share of new scripts, switches account for a modest percentage of the total, and that's possibly something where there was more of a bolus of such activity early in the launch. And as the launch progresses further, we expect that this may cease to be a motivating factor for some of those physicians; so overall, our focus is on those patients who are naive to CMI and who might benefit from adding MYQORZO to their regimen. That's where the velocity is coming from. That's where growth is coming from, and that's where we ultimately see the potential and the upside for MYQORZO. So thank you.

Robert Blum

executive
#88

Thank you, operator. To everyone joining us on today's call, I'd like to express my appreciation. Your ongoing backing and curiosity about what's happening at Cytokinetics mean a great deal to us. It's my honest view that the Q2 report we've shared is quite encouraging, and it speaks to the priorities we've said matter. Specifically, it addresses the way we move into commercial operations and create solid momentum and velocity for our launch, starting here in the United States and, we hope, while also laying groundwork in Europe. As that happens simultaneously, we're making better information available to guide patient and market access, and we're getting ready for what we anticipate will be a broader label that covers nHCM, drawing on the ACACIA data. Let me remind everyone that multiple presentations are planned, among them a hotline presentation at ESC later this month. Following that, an investor event is also on the way, and we're eager to share details with you from Munich. At the same time, we're pushing our pipeline forward — that's an essential principle and defining feature of the way we expect our business to expand over time, delivering value for patients, science, and shareholders. So with that, operator, we'll wrap up this call now, and we're very grateful for all the time and attention you've given us today.

Operator

operator
#89

Thank you. This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.